Proximagen (now BenevolentAI)

In February 2018, Proximagen Limited was acquired by BenevolentAI. Benevolent AI is one of the largest private AI companies in the world and the global leader in the development and application of AI for scientific innovation. The company is applying artificial intelligence to develop new medicines for hard to treat diseases. It is the first fully integrated AI company with pharmaceutical discovery and clinical development capabilities. BenevolentAI's advanced technology aims to lower drug development costs, decrease failure rates and increase the speed at which medicines are delivered to patients. The company's AI technology is being used to develop treatments to unmet patients' needs across a wide range of diseases, including Motor Neuron Disease, Parkinson's Disease, Glioblastoma and Sarcopenia. Proximagen has a long heritage in small molecule drug discovery and development, with an integrated drug discovery facility in Cambridge including in-house capabilities in medicinal chemistry, biology and drug metabolism and pharmacokinetics. The company was part of a US-based privately owned pharmaceutical group between August 2012 and February 2018, working together on drug development and translational medicine. See the BenevolentAI website for news, event and vacancy updates.